Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2015
Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of AutoimmunityPaul R Mangan, Linhui Julie Su, Victoria Jenny, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonistsZhonghui Lu, James J-W Duan, Haiyun Xiao, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Novel Tricyclic Pyroglutamide Derivatives as Potent RORγt Inverse Agonists Identified using a Virtual Screening ApproachQingjie Liu, Douglas G Batt, Carolyn A Weigelt, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.
Journal of Medicinal Chemistry|February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Science Translational Medicine|July 26, 2019
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domainJames R Burke, Lihong Cheng, Kathleen M Gillooly, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672Michael G Yang, Zili Xiao, Robert J Cherney, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Pageof 12